文献速递消化系统肿瘤

转移性结直肠癌基线液体活检与组织学参数的关系:随机FIRE-4(AIO-KRK-0114)研究结果

Baseline Liquid Biopsy in Relation to Tissue-Based Parameters in Metastatic Colorectal Cancer: Results From the Randomized FIRE-4 (AIO-KRK-0114) Study.
PubMed 文献 · J Clin Oncol · 2025-02-04

FIRE-4研究将一线RAS野生型转移性结直肠癌患者随机分配至FOLFIRI联合西妥昔单抗持续治疗组或FOLFIRI联合西妥昔单抗后换用FU联合贝伐珠单抗维持治疗组,比较基线液体活检与组织检测RAS/BRAF的结果。540例可评估患者中,液体活检检出RAS突变70例(13%)、BRAFV600E突变38例(7%),RAS突变者生存显著缩短。结论认为液体活检可检出组织学判定为RAS野生型患者的RAS和BRAF突变,这些患者转归与组织检测突变者一致。

要点

  • 组织学RAS野生型患者中,基线液体活检检出RAS突变13%、BRAFV600E突变7%。
  • 液体活检RAS突变者较RAS野生型者PFS和OS显著缩短。
  • 液体活检BRAFV600E突变者预后差,PFS 5.4个月、OS 12.0个月。

核心结论

  • 液体活检可在组织学判定为RAS野生型的患者中检出RAS和BRAF突变,这些患者的转归特征与组织检测RAS突变和BRAF突变患者一致。
  • 研究证实了在开始治疗前进行基线液体活检具有高度临床相关性。

研究设计与样本

  • FIRE-4研究为随机研究,将一线RAS野生型转移性结直肠癌患者随机分配至标准组(FOLFIRI联合西妥昔单抗持续至进展或不耐受)或试验组(FOLFIRI联合西妥昔单抗后换用FU联合贝伐珠单抗维持治疗)。
  • 共672例RAS野生型患者被随机分配,540例患者的基线液体活检可评估。
  • 液体活检在基线及治疗期间采集,采用体外诊断认证的ONCOBEAM RAS方法(Sysmex Inostics)和微滴数字聚合酶链反应技术检测RAS和BRAFV600E突变。

主要发现

  • 540例基线液体活检可评估患者中,RAS突变70例(13%),BRAFV600E突变38例(7%)。
  • 液体活检RAS突变患者较RAS野生型患者生存显著缩短:PFS 9.0个月 vs 11.5个月(P < .001;HR 1.66);OS 22.1个月 vs 33.6个月(P < .001;HR 1.85)。
  • 液体活检RAS突变患者中,早期换用维持治疗较继续FOLFIRI/西妥昔单抗的获益在数值上更大:PFS 10.1个月 vs 6.4个月(HR 0.82);OS 24.9个月 vs 16.3个月(HR 0.57)。
  • 液体活检BRAFV600E突变患者预后差:PFS 5.4个月,OS 12.0个月。
  • 基于系列液体活检分析,疾病进展时从RAS野生型转为RAS突变的转化率在持续西妥昔单抗治疗组显著高于换用维持治疗组。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The FIRE-4 study randomly assigned patients with first-line RAS wild-type (RASwt) metastatic colorectal cancer to either flourouracil (FU), folinic acid, and irinotecan (FOLFIRI) plus cetuximab until progression or intolerable toxicity (standard arm) or to FOLFIRI plus cetuximab followed by a switch maintenance treatment using FU plus bevacizumab (experimental arm). Here, we investigate the relevance of liquid biopsy (LB) RAS and BRAF testing compared with tissue-based analyses. PATIENTS AND METHODS: LBs were taken at baseline and during treatment and were analyzed for RAS and BRAFV600E mutations using the in vitro diagnostics-certified ONCOBEAM RAS procedure (Sysmex Inostics) and digital-droplet polymerase chain reaction technology. RESULTS: Six hundred seventy-two RASwt patients were randomly assigned. LBs of 540 patients were evaluable at baseline. Of those, 70 (13%) were RAS mutant (RASmut) and 38 (7%) BRAFV600E mutant. RASmut patients had significantly shorter survival compared with RASwt patients (progression-free survival [PFS], 9.0 months v 11.5 months; P < .001; hazard ratio [HR], 1.66; overall survival [OS], 22.1 months v 33.6 months; P < .001; HR, 1.85). RASmut patients had a numerically greater benefit from early switch maintenance compared with continuation of FOLFIRI/cetuximab (PFS, 10.1 months v 6.4 months; HR, 0.82; OS, 24.9 months v 16.3 months; HR, 0.57). Patients with a BRAFV600E mutation in LB showed poor outcome (PFS, 5.4 months; OS, 12.0 months). On the basis of serial LB analyses, the conversion rate from RASwt to RASmut at disease progression was significantly higher in the arm with continuous cetuximab administration than in the switch maintenance arm. CONCLUSION: LB allows the detection of RAS and BRAF mutations in patients deemed RASwt on the basis of tissue analyses. These patients show outcome characteristics expected for RAS- and BRAF-mutant patients in tissue. The study thus confirms the high clinical relevance of LB performed at baseline before the start of therapy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Stintzing S, Klein-Scory S, Fischer von Weikersthal L, et al. Baseline Liquid Biopsy in Relation to Tissue-Based Parameters in Metastatic Colorectal Cancer: Results From the Randomized FIRE-4 (AIO-KRK-0114) Study. J Clin Oncol. 2025. PMID: 39903881. doi:10.1200/JCO.24.01174

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。